Namba K, Nitanai H, Otani T, Azuma I
New Product Research Laboratories 1, Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan.
Vaccine. 1996 Oct;14(14):1322-6. doi: 10.1016/s0264-410x(96)00064-3.
We investigated the therapeutic effects of romurtide, a synthetic muramyl dipeptide derivative, on experimental thrombocytopenia induced by carboplatin in cynomolgus monkeys. A prolonged thrombocytopenia due to a severe myelosuppression was induced by carboplatin. Romurtide given subcutaneously elevated significantly the peripheral platelet counts during both early initiation and later recovery phase of thrombocytopenia, thereby shortening the time required for recovery to a normal platelet level and the duration of thrombocytopenia. An oral administration of romurtide was also found to have a similar therapeutic efficacy to subcutaneous administration. These results demonstrated a possible therapeutic potential of romurtide in the management of thrombocytopenia associated with myelosuppression.
我们研究了合成的胞壁酰二肽衍生物罗穆肽对食蟹猴中由卡铂诱导的实验性血小板减少症的治疗效果。卡铂诱导了由于严重骨髓抑制导致的血小板减少症持续时间延长。在血小板减少症的早期起始阶段和后期恢复阶段，皮下注射罗穆肽均显著提高了外周血小板计数，从而缩短了恢复到正常血小板水平所需的时间以及血小板减少症的持续时间。还发现口服罗穆肽具有与皮下注射相似的治疗效果。这些结果证明了罗穆肽在治疗与骨髓抑制相关的血小板减少症方面可能具有治疗潜力。
